+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pancreatic Cancer Drugs - Global Strategic Business Report

  • ID: 1227802
  • Report
  • Region: Global
  • 405 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Amgen, Inc. (USA)
  • Genentech Inc. (USA)
  • MORE
This report analyzes the Global market for Pancreatic Cancer Drugs in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The report profiles 57 companies including Abraxis BioScience, Inc., Amgen, Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd.., Genentech Inc., and OSI Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen, Inc. (USA)
  • Genentech Inc. (USA)
  • MORE
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. Executive Summary

1. MARKET REVIEW II-1
Current & Future Analysis II-1
High Unmet Need and Challenges Abound, But Hope Persists II-1
A Difficult to Diagnose and Treat Cancer II-1
At Odds with Life After Pancreatic Cancer II-2
Combination Therapies - A Potential Contender for Treatment II-2
Clinical Research - In Search of Breakthrough Therapy II-2
Active Pancreatic Cancer Pipeline - A Ray of Hope! II-2
Targeted Therapy - The Promise, The Potential! II-3
Research and Development - A Tough, Uphill Journey II-4
Clinical Trials Failure Flickers The Hope for Pancreatic
Cancer Treatment II-4
Gemcitabine Fixation Mars Pancreatic Cancer Research II-4
Competitive Landscape II-4
Select Approved Drugs for Metastatic Pancreatic Cancer II-5
United States - A Regional Overview II-5
Pancreatic Cancer - Incidence and Mortality II-5
Table 1: The American Cancer Society’s 5-year Relative
Survival Rate for Patients with Pancreatic Cancer by Disease
Stage II-6
Poor Prognosis, Late Diagnosis and High Unmet Needs - The
Challenges II-6
The Funding Face Off II-6
United Kingdom - A Regional Overview II-7
Pancreatic Cancer - Brits Patients Fighting for Survival II-7

2. PANCREATIC CANCER - THE STUDY OF A FATAL DISEASE II-8
Pancreas - The Vital Body Organ II-8
Pancreatic Cancer - The Devastating Disease II-8
Risk Factors of the Disease II-8
Prevention of the Disease II-9
Symptoms of the Disease II-9
Diagnosis of the Disease II-10
Abdominal Ultrasound II-10
CT Scan II-10
Percutaneous Biopsy II-10
Endoscopic Biopsy II-10
Treatment of the Disease II-11
Surgical Treatment II-11
Therapeutic Treatment II-11
Treatment with Chemotherapy Drugs II-12
Gemcitabine (Gemzar) II-12
Table 2: Gemzar Sales by Region: 2007 and 2008 (USD
Million) II-12
Fluorouracil (5-FU) II-13
Capecitabine (Xeloda) II-13
Treatment with Targeted Drug Therapy II-13
Erlotinib (Tarceva) II-13
Table 3: Tarceva Pancreatic Cancer Sales Worldwide:
2007-2012 (includes corresponding Graph/Chart) II-14
Treatment with Radiation Therapy II-14
Other Therapies II-15

3. RESEARCH & DEVELOPMENT II-16
Pfizer Announces Encouraging Results of Sutent, Stops Trial
Ahead of Schedule II-16
Abraxis BioScience Announces Interim Phase II Data for Abraxane II-16
Concordia Announces Phase I/II Trial Results of Pancreatic
Cancer Drug II-17
Infinity Pharma Announces Preclinical Data of IPI-926 II-17
Celsion and Philips Complete Feasibility Stage, Commence
Preclinical Development II-17
Mayo Clinic Reports Encouraging Test Results of a New Drug
Combination II-18
Sidney Kimmel Researchers Report Positive Tigatuzumab Plus
Gemcitabine Results II-18
NCI Scientists Discover New Approach to Treat Pancreatic Cancer II-19
Jefferson Researchers Report Potential of Herbal Extract in
Pancreatic Cancer II-19
American and Indian Scientists Discover New Pancreatic Cancer
Therapy II-20
Cambridge Scientists Discover Cause of Drug Failure in
Pancreatic Cancer II-20
CytRx Corp. Announces Trial Results of INNO-206 II-21
Amgen’s AMG 479 Shows Potential for Pancreatic Cancer Treatment II-21
BioCancell Receives FDA Approval for BC-819 Phase I/II Trials II-21
Rexahn Secures FDA Approval Phase II Trial of Archexin in
Pancreatic Cancer II-22
NeoPharm Files Application for Phase II Trial of LE-DT II-22
Regeneron and Sanofi-aventis Terminate Phase III Study of
Aflibercept II-22
Pfizer Terminates Phase III Clinical Study of Axitinib II-23
SciClone Terminates Phase II Trial of Pancreatic Cancer Drug II-23
MediGene Announces Final Results of Phase II EndoTAG-1 Study II-23
Abraxis BioScience Announces Positive Phase I Trial Results II-24
Immunomedics Announces Development of Novel Antibody-Drug
Conjugates II-24
Roche’s Study Shows Avastin Plus Tarceva to Benefit
Pancreatic Cancer Patients II-24
Morphotek Inaugurates Additional Phase II Study Sites in EU II-25
Pharmexa Announces Disappointing Data on GV1001, Terminates
Study II-25
Oncoscience to Commence New Phase IIb/IIIa Trial for Nimotuzumab II-25
Bristol-Myers and ImClone Announce Disappointing Phase III
Results of Erbitux II-26

4. RECENT INDUSTRY ACTIVITY II-27
Roche Acquires Genentech II-27
Sanofi-aventis Signs Agreement to Take Over BiPar Sciences II-27
Cell Genesys and BioSante Complete Merger II-27
Agennix and GPC Biotech Announce Merger II-28
YM BioSciences Plans Merger with Cytopia II-28
Myriad Acquires License to PALB2 Pancreatic Cancer Gene Patents II-28
Seattle Genetics, Agensys Expand ADC Collaboration II-29
Clavis Pharma Announces Agreement with Clovis Oncology for
Anti-cancer Drug II-29
GlobeImmune Enters into Strategic Global Oncology Alliance
with Celgene II-30
Rexahn and Teva Close Agreements for New Anti-cancer Agent,
RX-3117 II-30
Taiho Pharma Announces Termination of S-1 Agreement with
Sanofi-aventis II-30
Cancer Advances to Raise Funds for Pancreatic Cancer Drug Trial II-31
MacroChem Announces Virium Pharmaceuticals Acquisition II-31
DARA BioSciences and Point Therapeutics Merge II-31
GeneSense and Zor Sign Exclusive License Agreement for Virulizin II-31
Cobra and ViroMed Ink Agreement for Anti-cancer Drug Development II-32
GenVec and Cobra Ink Manufacturing Agreement II-32
ARIUS Research and Laureate Pharma Ink Agreement for Trop-2 II-32

5. REGULATORY SUBMISSIONS AND APPROVALS II-33
Chugai Submits Application for Additional Indication of
Pancreatic Cancer II-33
MediGene Secures FDA’s Orphan Drug Designation for Anti-
cancer Candidate II-33
Antisense Announces FDA and EMEA Orphan Drug Designation for
Trabedersen II-33
Clavis Announces EMEA’s Orphan Drug Recommendation for CP-4126 II-34
Epeius Receives FDA’s Fast Track Designation for Rexin-G II-34
Abraxis BioScience Receives FDA’s Orphan Drug Status for
Abraxane II-34
Immunomedics Announces Fast Track Designation of FDA for hPAM4 II-35
Oncotherapy Science Plans Filing for Approval of Pancreatic
Cancer Vaccine II-35
GenVec Announces FDA’s Fast Track Designation for TNFerade II-35
PharmaEngine Receives FDA’s Approval for PEP02 IND Application II-36
Reata Receives FDA’s Orphan Drug Status for Anti-cancer drug,
RTA 402 II-36
Marshall Edwards Announces FDA Orphan Drug Designation for
Triphendiol II-36
Tau Receive FDA’s Orphan Drug Status for Pancreatic Cancer
Treatment II-36
Regulon Receives Orphan Designation for Pancreatic Cancer
Candidate, Cisplatin II-37
Roche Wins European Approval for Tarceva II-37

6. FOCUS ON SELECT PLAYERS II-38
Abraxis BioScience, Inc. (USA) II-38
Amgen, Inc. (USA) II-38
Eli Lilly and Company (USA) II-38
F. Hoffmann-La Roche Ltd. (Switzerland) II-39
Genentech Inc. (USA) II-39
OSI Pharmaceuticals, Inc. (USA) II-40

7. GLOBAL MARKET PERSPECTIVE II-41
Table 4: World Recent Past, Current & Future Analysis for
Pancreatic Cancer Drugs - Annual Sales Figures in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-41

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 57 (including Divisions/Subsidiaries - 61)

Region/Country Players

The United States 37
Canada 2
Japan 5
Europe 12
France 1
Germany 5
The United Kingdom 1
Spain 1
Rest of Europe 4
Asia-Pacific (Excluding Japan) 4
Middel East 1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abraxis BioScience, Inc. (USA)
  • Amgen, Inc. (USA)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genentech Inc. (USA)
  • OSI Pharmaceuticals, Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/1227802
Adroll
adroll